AR113429A1 - Terapia combinada de agonistas de icos dirigidos a tumores con moléculas biespecíficas de linfocitos t - Google Patents

Terapia combinada de agonistas de icos dirigidos a tumores con moléculas biespecíficas de linfocitos t

Info

Publication number
AR113429A1
AR113429A1 ARP180103770A ARP180103770A AR113429A1 AR 113429 A1 AR113429 A1 AR 113429A1 AR P180103770 A ARP180103770 A AR P180103770A AR P180103770 A ARP180103770 A AR P180103770A AR 113429 A1 AR113429 A1 AR 113429A1
Authority
AR
Argentina
Prior art keywords
binding
antigen
molecules
icus
lymphocytes
Prior art date
Application number
ARP180103770A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR113429A1 publication Critical patent/AR113429A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente se refiere a moléculas de unión a ICOS agonistas que comprenden al menos un dominio de unión a antígeno que se une a un antígeno asociado con tumores y a su uso en combinación con moléculas biespecíficas de linfocitos T en el tratamiento del cáncer, a las moléculas de unión a ICOS agonistas en sí, a composiciones farmacéuticas que comprenden estas moléculas y a métodos para usar las mismas. Reivindicación 1: Una molécula de unión a ICOS agonista que comprende al menos un dominio de unión a antígeno capaz de unirse de manera específica a un antígeno asociado a tumores para usarse en un método para el tratamiento o retraso de la progresión de cánceres, en donde la molécula de unión a ICOS agonista que comprende al menos un dominio de unión a antígeno capaz de unirse de manera específica a un antígeno asociado a tumores se usa en combinación con un anticuerpo biespecífico anti-CD3 de activación de linfocitos T, específico para un antígeno asociado a tumores.
ARP180103770A 2017-12-21 2018-12-20 Terapia combinada de agonistas de icos dirigidos a tumores con moléculas biespecíficas de linfocitos t AR113429A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17209444.3A EP3502140A1 (en) 2017-12-21 2017-12-21 Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules

Publications (1)

Publication Number Publication Date
AR113429A1 true AR113429A1 (es) 2020-04-29

Family

ID=60702548

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180103770A AR113429A1 (es) 2017-12-21 2018-12-20 Terapia combinada de agonistas de icos dirigidos a tumores con moléculas biespecíficas de linfocitos t

Country Status (13)

Country Link
US (2) US20200306373A1 (es)
EP (2) EP3502140A1 (es)
JP (1) JP2021506293A (es)
KR (1) KR20200104332A (es)
CN (1) CN111465619A (es)
AR (1) AR113429A1 (es)
AU (1) AU2018392753A1 (es)
BR (1) BR112020012105A2 (es)
CA (1) CA3084114A1 (es)
IL (1) IL275316A (es)
MX (1) MX2020006116A (es)
TW (1) TW201936639A (es)
WO (1) WO2019122049A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3619235A1 (en) 2017-04-11 2020-03-11 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
CN112789294A (zh) * 2018-07-24 2021-05-11 印希比股份有限公司 含有受限cd3结合结构域和受体结合区的多特异性多肽构建体及其使用方法
US20200223925A1 (en) * 2018-12-21 2020-07-16 Hoffmann-La Roche Inc. Tumor-targeted superagonistic cd28 antigen binding molecules
WO2020260326A1 (en) * 2019-06-27 2020-12-30 F. Hoffmann-La Roche Ag Novel icos antibodies and tumor-targeted antigen binding molecules comprising them
EP4136112A1 (en) * 2020-04-14 2023-02-22 GlaxoSmithKline Intellectual Property Development Limited Combination treatment for cancer
CN114539416A (zh) * 2020-11-26 2022-05-27 盛禾(中国)生物制药有限公司 一种双特异性抗体的层析纯化工艺
CN113603789A (zh) * 2021-07-30 2021-11-05 宝诺威(苏州)生物技术有限公司 一种定向定量标记生物素的抗体及其制备方法与应用
CN117940460A (zh) * 2021-09-08 2024-04-26 上海齐鲁制药研究中心有限公司 双特异性抗原结合分子及其应用
WO2023219120A1 (ja) * 2022-05-12 2023-11-16 アステラス製薬株式会社 抗ｃｄ３７－抗ｃｄ３二重特異性抗体

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2013110A (en) 1933-01-10 1935-09-03 Maiden Form Brassiere Co Inc Brassiere
FR2388385B1 (fr) 1977-04-18 1982-01-08 Hitachi Metals Ltd Piece d'ornement fixee par des aimants permanents
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
JP3521382B2 (ja) * 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ATE296315T1 (de) 1997-06-24 2005-06-15 Genentech Inc Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
AU759779B2 (en) 1997-10-31 2003-05-01 Genentech Inc. Methods and compositions comprising glycoprotein glycoforms
JP4460155B2 (ja) 1997-12-05 2010-05-12 ザ・スクリプス・リサーチ・インステイチユート マウス抗体のヒト化
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
ATE458007T1 (de) 1998-04-20 2010-03-15 Glycart Biotechnology Ag Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
EP2386574A3 (en) 1999-01-15 2012-06-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
SI1149114T1 (sl) * 1999-02-03 2014-08-29 Amgen Inc. Polipeptidi, vkljuäśeni v imunskem odgovoru
CA2385347C (en) 1999-10-04 2009-12-15 Medicago Inc. Method for regulating transcription of foreign genes
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
NZ571596A (en) 2001-08-03 2010-11-26 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
EP1443961B1 (en) 2001-10-25 2009-05-06 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
AU2004253835B2 (en) 2003-07-04 2009-01-29 Affibody Ab Polypeptides having binding affinity for HER2
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
ME03330B (me) 2003-11-05 2019-10-20 Roche Glycart Ag Cd20 antitijela sa povećanim afinitetom za vezivanje fc receptora i efektornom funkcijom
KR20060129246A (ko) 2003-12-05 2006-12-15 컴파운드 쎄라퓨틱스, 인크. 타입 2 혈관 내피 성장 인자 수용체의 억제제
AU2005230848B9 (en) 2004-03-31 2011-06-02 Genentech, Inc. Humanized anti-TGF-beta antibodies
US7521541B2 (en) 2004-09-23 2009-04-21 Genetech Inc. Cysteine engineered antibodies and conjugates
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP5399712B2 (ja) 2005-12-21 2014-01-29 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー 可溶性ｃｅａに対する抵抗性を有する医薬組成物
EP1958957A1 (en) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprising a knottin protein moiety
EP2235064B1 (en) 2008-01-07 2015-11-25 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
JP5960597B2 (ja) * 2009-09-30 2016-08-02 メモリアル スローン−ケタリング キャンサー センター 癌治療のための併用免疫療法
CA2806021C (en) 2010-08-13 2019-05-21 Roche Glycart Ag Anti-fap antibodies and methods of use
KR101614195B1 (ko) 2011-03-29 2016-04-20 로슈 글리카트 아게 항체 Fc 변이체
WO2013012414A1 (en) * 2011-07-18 2013-01-24 Medimmune, Llc Dosing regimens for treatment of cea-expressing cancers
WO2013026837A1 (en) * 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
TWI664192B (zh) 2012-11-20 2019-07-01 法商賽諾菲公司 抗ｃｅａｃａｍ５抗體及其用途
RS59992B1 (sr) 2013-02-26 2020-04-30 Roche Glycart Ag Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije specifični za cd3 i cea
CN110845618A (zh) * 2013-02-26 2020-02-28 罗切格利卡特公司 双特异性t细胞活化抗原结合分子
UA118028C2 (uk) * 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
GB2519786A (en) * 2013-10-30 2015-05-06 Sergej Michailovic Kiprijanov Multivalent antigen-binding protein molecules
US20170015758A1 (en) * 2014-01-21 2017-01-19 Medimmune, Llc Compositions And Methods For Modulating And Redirecting Immune Responses
EP2982693A1 (en) * 2014-08-07 2016-02-10 Affimed Therapeutics AG CD3 binding domain
BR112016030670A2 (pt) 2014-08-29 2017-10-31 Hoffmann La Roche "imunocitoquina"
NZ767672A (en) * 2014-11-14 2024-02-23 Hoffmann La Roche Antigen binding molecules comprising a tnf family ligand trimer
MX2017006571A (es) 2014-11-20 2017-09-29 Hoffmann La Roche Moleculas de union a antigeno biespecificas activadoras de celulas t.
EP3245227A4 (en) * 2015-01-14 2018-07-25 Compass Therapeutics LLC Multispecific immunomodulatory antigen-binding constructs
CN114773486A (zh) * 2015-04-17 2022-07-22 高山免疫科学股份有限公司 具有可调的亲和力的免疫调节蛋白
WO2017055398A2 (en) * 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific antibodies specific for a costimulatory tnf receptor
EP3231813A1 (en) * 2016-03-29 2017-10-18 F. Hoffmann-La Roche AG Trimeric costimulatory tnf family ligand-containing antigen binding molecules
EP3464367B1 (en) * 2016-05-27 2020-09-09 AbbVie Biotherapeutics Inc. Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
CN106589129B (zh) * 2016-12-30 2021-03-05 上海近岸生物科技有限公司 一种结合cd19、cd3和cd28的三功能分子及其应用
US11535666B2 (en) * 2016-12-30 2022-12-27 Cytocares (Shanghai) Inc. Trifunctional molecule and application thereof

Also Published As

Publication number Publication date
US20230355754A1 (en) 2023-11-09
TW201936639A (zh) 2019-09-16
EP3502140A1 (en) 2019-06-26
CA3084114A1 (en) 2018-12-20
BR112020012105A2 (pt) 2020-11-24
IL275316A (en) 2020-07-30
KR20200104332A (ko) 2020-09-03
US20200306373A1 (en) 2020-10-01
JP2021506293A (ja) 2021-02-22
WO2019122049A1 (en) 2019-06-27
EP3728325A1 (en) 2020-10-28
CN111465619A (zh) 2020-07-28
AU2018392753A1 (en) 2020-06-11
MX2020006116A (es) 2020-08-24

Similar Documents

Publication Publication Date Title
AR113429A1 (es) Terapia combinada de agonistas de icos dirigidos a tumores con moléculas biespecíficas de linfocitos t
PH12020551689A1 (en) Her2-targeting antigen binding molecules comprising 4-1bbl
CY1123977T1 (el) Anti-pd-1 και anti-lag3 αντισωματα για την θεραπεια του καρκινου
CY1124791T1 (el) Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων
BR112019022495A2 (pt) Conjugados de anticorpo que compreendem agonista de receptor similar a toll e terapias de combinação
CL2021000353A1 (es) Anticuerpo o fragmento de anticuerpo del mismo que comprende una región de unión que se une a un supresor del dominio vista, composición que lo comprende, su uso para tratar o prevenir el cáncer, ácido nucleico aislado, vector de expresión, célula hospedadora, método para producir dicho anticuerpo o fragmento del mismo, y artículo de fabricación (divisional de solicitud n° 01646-2016)
AR107442A1 (es) Anticuerpos contra el receptor huérfano similar al receptor tirosina quinasa 1 (anti-ror1), anticuerpos biespecíficos que se unen a ror1 y al antígeno cd3, y métodos para el tratamiento del cáncer
PE20210288A1 (es) Anti-cd25 para el agotamiento de celulas tumorales especificas
MX2020004573A (es) Terapia de combinacion con agonistas de ox40 dirigidos.
EP4269594A3 (en) Combination therapies for treatment of bcma-related cancers and autoimmune disorders
MX2019006954A (es) Terapia de combinacion de anticuerpos biespecificos anti-cd20/anti-cd3 y agonistas de 4-1bb (cd137).
AR106570A1 (es) Anticuerpos anti-psma, moléculas de unión al antígeno biespecíficas que se unen a psma y cd3, y usos de estos
EA201691858A1 (ru) Композиции антител для лечения опухолей
BR112018007296A2 (pt) conjugados de anticorpo compreendendo agonista de receptor tipo toll
BR112016030740A2 (pt) diacorpos heterodiméricos biespecíficos e seus usos
PE20210167A1 (es) Proteinas de union multiespecificas y mejoras con estas
PE20210375A1 (es) Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales
EA201990183A1 (ru) Аденовирус, вооруженный биспецифичным активатором т-клеток (bite)
MX2020009468A (es) Terapias de combinacion de agonistas de 4-1bb con anticuerpos anti-cd20.
BR112015027309A2 (pt) anticorpo, composição, método de tratamento e uso de um anticorpo
BR112019023909A8 (pt) Uso de um imunoconjugado que se liga a folr1, e, uso de um imunoconjugado que se liga a folr1 e pembrolizumab
AR114437A1 (es) Conjugados para el direccionamiento hacia agregados y para la eliminación de los mismos
CY1124183T1 (el) Συζευγματα αντισωματος εναντι-sez6 φαρμακου και μεθοδοi χρησης
CL2020002338A1 (es) Anti–cd25 para el agotamiento de células específicas de tumores
MX2021001604A (es) Tratamiento del cáncer con un anticuerpo.